DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Jones Financial Companies Lllp

Jones Financial Companies Lllp increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 43.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,916 shares of the medical device company's stock after acquiring an additional 3,291 shares during the quarter. Jones Financial Companies Lllp's holdings in DexCom were worth $849,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Blue Whale Capital LLP raised its position in shares of DexCom by 91.9% in the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after purchasing an additional 113,000 shares during the period. Brooktree Capital Management purchased a new stake in shares of DexCom during the third quarter valued at approximately $683,000. Motley Fool Asset Management LLC grew its holdings in shares of DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock worth $17,993,000 after purchasing an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC purchased a new position in shares of DexCom in the fourth quarter worth $3,334,000. Finally, Congress Asset Management Co. raised its holdings in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DXCM. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and boosted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Finally, Wells Fargo & Company lifted their price target on shares of DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average price target of $99.82.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the firm's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,083 shares of company stock worth $3,309,794. Company insiders own 0.30% of the company's stock.

DexCom Stock Performance

Shares of DXCM traded down $1.67 during trading hours on Friday, hitting $77.84. The stock had a trading volume of 3,861,055 shares, compared to its average volume of 3,717,810. The firm has a market capitalization of $30.42 billion, a PE ratio of 54.43, a PEG ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a fifty day moving average price of $84.83 and a 200 day moving average price of $76.99.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.